- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04305470
Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma (MEN-301)
A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This Phase 3 open-label single-arm study is designed to investigate the safety, diagnostic performance, and clinical usefulness of the imaging agent Gleolan™ (Aminolevulinic Acid Hydrochloride, ALA HCl, ALA, 5-ALA), an orally administered imaging agent for the real time detection and visualization of meningiomas during tumor resection surgery. ALA is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). The exogenous application of ALA leads to a highly selective accumulation of PpIX in tumor cells. Following excitation with blue light (BL) (λ = 375 - 440 nm), the PpIX, which has accumulated selectively in tumor tissue, emits a red-violet light. This phenomenon allows for the real-time visualization of tumor tissue during resection surgery.
Patients about to undergo resection for suspected meningioma [World Health Organization (WHO) Grade I, II, III] will be screened and informed consent will be obtained prior to surgery and prior to study participation. Eligible study participants will receive an oral solution of Gleolan (20 mg/kg body weight) 3 hours, (target range 2-4 hours) prior to anesthesia, and then undergo surgery for meningioma resection. During the surgery, the surgeon will use a microscope equipped with WL and BL for visualization of Gleolan-induced PpIX fluorescence for the selection of protocol-driven tissue locations and to assess fluorescence status.
Study participants will be evaluated within 48 hours post procedure, 2 weeks post procedure, and 6 weeks post procedure for study safety assessment.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Medical University of Vienna
-
-
-
-
-
Münster, Germany
- University Hospital Münster
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Mayo Clinic
-
-
California
-
La Jolla, California, United States, 92093
- University of California San Diego
-
Los Angeles, California, United States, 90033
- Keck Hospital of USC
-
Orange, California, United States, 92868
- Providence St. Joseph Hospital
-
-
Colorado
-
Englewood, Colorado, United States, 80113
- Swedish Medical Center
-
-
Florida
-
Coral Gables, Florida, United States, 33136
- University of Miami
-
Miami, Florida, United States, 33176
- Baptist Health South Florida
-
-
Illinois
-
Springfield, Illinois, United States, 62702
- Southern Illinois University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Health System
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Rochester
-
-
New York
-
Brooklyn, New York, United States, 11220
- NYU Langone Health
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania- Penn Medicine
-
Pittsburgh, Pennsylvania, United States, 15213
- UPMC
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A pre-operative MRI within ≥ 90 days of study enrollment documenting a suspected meningioma or suspected recurrence of a meningioma for which a meningioma resection is indicated and has been planned.
- Adult age ≥ 18 years.
- Patient must have normal organ and bone marrow function and be appropriate surgical candidates per site SOC.
Patient must have recording of each parameter as defined below:
Bilirubin Below upper limit of normal AST (SGOT) < 2.5 X institutional upper limit of normal ALT (SGPT) < 2.5 X institutional upper limit of normal Creatinine Below upper limit of normal OR Creatinine clearance >60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal
- The patient must demonstrate the ability to understand the informed consent document and the willingness and ability to sign a written informed consent document. The study consent documents will be prepared in English and German and Spanish. Translation for non-English, non-German, or non-Spanish speaking participants will be provided as appropriate by institution, as required.
- WOCBP and men participating must agree to use highly effective forms of contraception, and men must also agree not to donate sperm for the duration of treatment, and for at least 42 days after the one time use of the study drug.
Exclusion Criteria:
- History of allergic reactions attributed to compounds of similar chemical/biologic composition to Gleolan.
- Known or documented personal or family history of porphyria.
- Uncontrolled concurrent illness, including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness.
- Patient has had a meningioma resection or radiation treatment within 90 days of informed consent.
- Social or medical situations that would limit compliance with study requirements (e.g. ability to travel for follow-up or inability to obtain appropriate pre-op MRI (e.g. cardiac pacemaker).
- Women who are pregnant or plan to become pregnant during study participation.
- Prior history of gastrointestinal perforation, diverticulitis, and or/peptic ulcer disease within 90 days of informed consent.
- Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding treatment or within 5 plasma half-life of the preceding study drug, whatever is longer.
- Simultaneous use of other potentially phototoxic substances (St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones and tetracyclines), and topical preparations containing ALA for 24 hours during the perioperative period (see MOPS for detailed list).
- Unwillingness by patient to sign consent or return for subsequent visits following surgery.
- Any condition that in the opinion of the Investigator would exclude the patient as a viable candidate for this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm
Open-label, single-arm
|
One time oral dose on day of surgery (20 mg/kg bodyweight)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of participants who have at least one indeterminate tissue or unexpected fluorescent End of Surgery (EOS) tissue where Gleolan-induced PpIX fluorescence status is consistent with histology.
Time Frame: Surgery (Day 1)
|
Per Protocol Population
|
Surgery (Day 1)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive Predicted Value (PPV) of Gleolan-induced PpIX fluorescence of the single bulk tumor tissue obtained from each study participant
Time Frame: Surgery (Day 1)
|
Per Protocol Population
|
Surgery (Day 1)
|
Diagnostic accuracy of Gleolan-induced PpIX fluorescence among indeterminate tissue and unexpected fluorescent EOS tissue locations is at least 20% greater than the diagnostic accuracy of the surgeons' assessment.
Time Frame: Surgery (Day 1)
|
Biopsy Efficacy Analysis Population
|
Surgery (Day 1)
|
Diagnostic performance of Gleolan-induced PpIX fluorescence will be computed for indeterminate tissue biopsies, unexpected fluorescent EOS tissue biopsies.
Time Frame: Surgery (Day 1)
|
Biopsy Efficacy Analysis Population
|
Surgery (Day 1)
|
The concordance between the Surgeon and Adjudication Panel assessment of white light (WL) visualization visualization to identify tissue as likely or unlikely to be meningioma among indeterminate tissues.
Time Frame: Surgery (Day 1)
|
Biopsy Efficacy Analysis Population
|
Surgery (Day 1)
|
The concordance between the Surgeon and Adjudication Panel assessment of blue light (BL) visualization to identify fluorescence status of indeterminate tissues.
Time Frame: Surgery (Day 1)
|
Biopsy Efficacy Analysis Population
|
Surgery (Day 1)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Walter Stummer, MD, Universitätsklinikum Münster
- Principal Investigator: Bernard Bendok, MD, Mayo Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NXDC-MEN-301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meningioma
-
University Hospital, MontpellierCentre Hospitalier Universitaire de BesanconRecruitingAtypical Meningioma | Anaplastic Meningioma | Clear-cell Meningioma | Chordoid Meningioma | Rhabdoid Meningioma | Papillary MeningiomaFrance
-
Northwestern UniversityNational Cancer Institute (NCI); NovoCure Ltd.RecruitingAtypical Meningioma | Grade III Meningioma | Recurrent Meningioma | Anaplastic (Malignant) Meningioma | Grade II Meningioma | Supratentorial MeningiomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingGrade 1 Meningioma | Grade 2 Meningioma | Grade 3 Meningioma | Recurrent Meningioma | Unresectable MeningiomaUnited States
-
Nancy Ann Oberheim Bush, MDMerck Sharp & Dohme LLCRecruitingRecurrent Meningioma | Grade I Meningioma, Adult | Grade II Meningioma, Adult | Grade III Meningioma, AdultUnited States
-
National Cancer Institute (NCI)RecruitingGrade 2 Meningioma | Grade 3 Meningioma | Recurrent MeningiomaUnited States
-
University of NebraskaChimerixNot yet recruitingMeningioma | Refractory Meningioma | Relapsed MeningiomaUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingIntracranial Meningioma | Grade II MeningiomaCanada, United States, Japan, Saudi Arabia, India
-
Ohio State UniversityRecruitingCognitive Impairment | Cognitive Decline | Meningioma | Skull Base Meningioma | Frontal Meningioma | Temporal Meningioma | Post-Surgical CognitionUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingMeningioma | Anaplastic Meningioma | Meningioma AtypicalItaly
-
National Cancer Institute (NCI)CompletedRecurrent Adult Brain Tumor | Adult Grade I Meningioma | Adult Grade II Meningioma | Adult Meningeal Hemangiopericytoma | Adult Meningioma | Adult Grade III MeningiomaUnited States
Clinical Trials on Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)
-
Steven W ThorpeNational Cancer Institute (NCI)Not yet recruitingSoft Tissue Sarcoma | Soft Tissue Sarcoma AdultUnited States
-
Alpheus Medical, Inc.Active, not recruitingHigh Grade GliomaUnited States
-
Sociedad de Lucha Contra el Cáncer del EcuadorNot yet recruitingGlioma | Neoplasms, Neuroepithelial | Neuroectodermal Tumors | Central Nervous System Neoplasms | Brain Tumor | High Grade Glioma | Glioma, Malignant | Neoplasm Malignant | Photosensitizing Agents | Tumour, Residual | Brain Neoplasms, Adult, MalignantEcuador
-
Constantinos HadjipanayisNational Cancer Institute (NCI); NX PharmaGenWithdrawnGlioblastoma | Brain Cancer | Brain Tumors | Brain Tumor, Recurrent | Benign Neoplasms, Brain | Brain Neoplasms, Benign | Brain Neoplasms, Malignant | Brain Tumor, Primary | Intracranial Neoplasms | Neoplasms, Brain | Neoplasms, Intracranial | Primary Brain Neoplasms | Primary Malignant Brain Neoplasms | Primary Malignant... and other conditionsUnited States
-
University of HawaiiSBI ALApromo Co., Ltd. - Strategic Business InnovatorCompletedStress | Insomnia | Irritability | Coping Behavior | Nocturnal AwakeningUnited States
-
National Cancer Institute (NCI)TerminatedOral LeukoplakiaUnited States
-
Michael Vogelbaum, MD, PhDNational Cancer Institute (NCI)TerminatedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain TumorUnited States
-
medac GmbHIKPCompleted
-
David W. RobertsNational Institute of Neurological Disorders and Stroke (NINDS); Carl Zeiss...RecruitingBrain CancerUnited States
-
University of Alabama at BirminghamDUSA Pharmaceuticals, Inc.CompletedToenail Onychomycosis | Distal and Lateral Subungual Toenail OnychomycosisUnited States